The human 6-transmembrane epithelial antigen of prostate (STEAP) family comprises
STEAP1, STEAP2, STEAP3, and STEAP4. All of these proteins are unique to mammals and …

Immunotherapy has failed to achieve durable remissions in advanced prostate cancer
patients. More potent T-cell–redirecting strategies may be needed to overcome the …

Simple Summary Despite recent therapeutic advances in the treatment of prostate cancer,
metastatic castration-resistant prostate cancer continues to cause significant morbidity and …

Antigen-specific priming of human, naive T cells has been difficult to assess. Owing to the
low initial frequency in the naive cell pool of specific T cell precursors, such an analysis has …

Recent evidence suggests that dysregulation of iron regulatory factors may play essential
roles in cancer pathophysiology. Six-transmembrane epithelial antigen of prostate 3 …

Six-transmembrane epithelial antigen of the prostate-1 (STEAP-1) is a novel cell surface
protein highly expressed in primary prostate cancer, with restricted expression in normal …

Among currently available vaccine strategies for cancer, nucleotide-based vaccination is an
appealing treatment modality. Curevacs' mRNA containing vaccines (RNActive®) combine …

The six-transmembrane epithelial antigen of prostate (STEAP) protein was identified in
advanced prostate cancer and is up-regulated in multiple cancer cell lines, including …

Immunotherapy may provide an alternative treatment for cancer patients, especially when
tumors overexpress antigens that can be recognized by immune cells. The identification of …

Simple Summary Ewing sarcoma (EwS) is a highly aggressive and metastatic cancer in
children and adolescents. Canonical therapy mainly comprises the combination of intensive …